Embracing Imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19

Chia Siang Kow; Dinesh Sangarran Ramachandram; Syed Shahzad Hasan

doi:10.1007/s10456-023-09889-2

Embracing Imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19

Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan

Research output: Contribution to journal › Letter › peer-review

Abstract

Imatinib, an ABL tyrosine-kinase inhibitor, shows promise in restoring endothelial barrier function in patients with COVID-19, thus, preventing cytokine leakage from the alveolar compartment to the systemic compartment. COVID-19 is characterized by an alveolar cytokine storm, and imatinib has been shown to strengthen the endothelial barrier and mitigate alveolar inflammatory responses by modulating NF-κB signaling. Incorporating imatinib into COVID-19 treatment strategies offers a novel approach to safeguard the endothelial barrier and address the complex pathophysiology of the disease, including its potential implications in long COVID. Given that endothelial dysfunction plays a central role in COVID-19 progression and long COVID development, protecting the endothelial barrier during acute infection is crucial in preventing the persistent endothelial dysfunction associated with long COVID.

Original language	English
Pages (from-to)	481-483
Number of pages	3
Journal	Angiogenesis
Volume	26
Issue number	4
Early online date	2 Aug 2023
DOIs	https://doi.org/10.1007/s10456-023-09889-2
Publication status	Published - 1 Nov 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10456-023-09889-2Licence: Unspecified

Cite this

@article{e66c93fa199c40a08eadf070908904ee,

title = "Embracing Imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19",

abstract = "Imatinib, an ABL tyrosine-kinase inhibitor, shows promise in restoring endothelial barrier function in patients with COVID-19, thus, preventing cytokine leakage from the alveolar compartment to the systemic compartment. COVID-19 is characterized by an alveolar cytokine storm, and imatinib has been shown to strengthen the endothelial barrier and mitigate alveolar inflammatory responses by modulating NF-κB signaling. Incorporating imatinib into COVID-19 treatment strategies offers a novel approach to safeguard the endothelial barrier and address the complex pathophysiology of the disease, including its potential implications in long COVID. Given that endothelial dysfunction plays a central role in COVID-19 progression and long COVID development, protecting the endothelial barrier during acute infection is crucial in preventing the persistent endothelial dysfunction associated with long COVID.",

keywords = "Imatinib, COVID 19, endothelial barrier",

author = "Kow, \{Chia Siang\} and Ramachandram, \{Dinesh Sangarran\} and Hasan, \{Syed Shahzad\}",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s), under exclusive licence to Springer Nature B.V.",

year = "2023",

month = nov,

day = "1",

doi = "10.1007/s10456-023-09889-2",

language = "English",

volume = "26",

pages = "481--483",

journal = "Angiogenesis",

issn = "0969-6970",

publisher = "Springer Science and Business Media B.V.",

number = "4",

}

TY - JOUR

T1 - Embracing Imatinib

T2 - a novel approach to safeguarding the endothelial barrier in patients with COVID-19

AU - Kow, Chia Siang

AU - Ramachandram, Dinesh Sangarran

AU - Hasan, Syed Shahzad

PY - 2023/11/1

Y1 - 2023/11/1

N2 - Imatinib, an ABL tyrosine-kinase inhibitor, shows promise in restoring endothelial barrier function in patients with COVID-19, thus, preventing cytokine leakage from the alveolar compartment to the systemic compartment. COVID-19 is characterized by an alveolar cytokine storm, and imatinib has been shown to strengthen the endothelial barrier and mitigate alveolar inflammatory responses by modulating NF-κB signaling. Incorporating imatinib into COVID-19 treatment strategies offers a novel approach to safeguard the endothelial barrier and address the complex pathophysiology of the disease, including its potential implications in long COVID. Given that endothelial dysfunction plays a central role in COVID-19 progression and long COVID development, protecting the endothelial barrier during acute infection is crucial in preventing the persistent endothelial dysfunction associated with long COVID.

AB - Imatinib, an ABL tyrosine-kinase inhibitor, shows promise in restoring endothelial barrier function in patients with COVID-19, thus, preventing cytokine leakage from the alveolar compartment to the systemic compartment. COVID-19 is characterized by an alveolar cytokine storm, and imatinib has been shown to strengthen the endothelial barrier and mitigate alveolar inflammatory responses by modulating NF-κB signaling. Incorporating imatinib into COVID-19 treatment strategies offers a novel approach to safeguard the endothelial barrier and address the complex pathophysiology of the disease, including its potential implications in long COVID. Given that endothelial dysfunction plays a central role in COVID-19 progression and long COVID development, protecting the endothelial barrier during acute infection is crucial in preventing the persistent endothelial dysfunction associated with long COVID.

KW - Imatinib

KW - COVID 19

KW - endothelial barrier

UR - https://www.scopus.com/pages/publications/85166403232

U2 - 10.1007/s10456-023-09889-2

DO - 10.1007/s10456-023-09889-2

M3 - Letter

C2 - 37530975

AN - SCOPUS:85166403232

SN - 0969-6970

VL - 26

SP - 481

EP - 483

JO - Angiogenesis

JF - Angiogenesis

IS - 4

ER -

Embracing Imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this